{
  "symbol": "REGN",
  "date": "2025-10-05",
  "headlines": [
    {
      "date": "2025-10-02",
      "time": "16:55",
      "title": "Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management\n\n\n(Insider Monkey)",
      "link": "/news/182750/regeneron-regn-highlights-benefits-of-semaglutide-and-trevogrumab-in-obesity-management"
    },
    {
      "date": "2025-10-05",
      "time": "09:45AM",
      "title": "Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough\n\n\n(Insider Monkey)",
      "link": "/news/182265/regeneron-pharmaceuticals-inc-regn-draws-attention-with-rare-disease-breakthrough"
    },
    {
      "date": "2025-10-01",
      "time": "20:10",
      "title": "Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials\n\n\n(Insider Monkey)  +6.70%",
      "link": "/news/181699/regeneron-pharmaceuticals-inc-regn-reports-positive-results-from-several-late-stage-trials"
    },
    {
      "date": "2025-10-05",
      "time": "02:16AM",
      "title": "Regeneron's Evkeeza Receives FDA Approval to Treat HoFH in Children Aged 1 to Less Than 5\n\n\n(Insider Monkey)",
      "link": "/news/180427/regenerons-evkeeza-receives-fda-approval-to-treat-hofh-in-children-aged-1-to-less-than-5"
    },
    {
      "date": "2025-09-30",
      "time": "16:05",
      "title": "Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025\n\n\n(GlobeNewswire)",
      "link": "/news/180118/regeneron-to-report-third-quarter-2025-financial-and-operating-results-and-host-conference-call-and-webcast-on-october-28-2025"
    },
    {
      "date": "2025-10-05",
      "time": "07:30AM",
      "title": "2 Beaten-Down Stocks to Buy and Hold for a Decade\n\n\n(Motley Fool)",
      "link": "/news/179313/2-beaten-down-stocks-to-buy-and-hold-for-a-decade"
    },
    {
      "date": "2025-09-29",
      "time": "14:53",
      "title": "Regeneron (REGN) Gains Attention With Successful Phase 3 Garetosmab Trial for Rare Disease\n\n\n(Insider Monkey)",
      "link": "/news/178711/regeneron-regn-gains-attention-with-successful-phase-3-garetosmab-trial-for-rare-disease"
    },
    {
      "date": "2025-10-05",
      "time": "10:43AM",
      "title": "Here's Why Regeneron Pharmaceuticals (REGN) Fell in Q2\n\n\n(Insider Monkey)",
      "link": "/news/178498/heres-why-regeneron-pharmaceuticals-regn-fell-in-q2"
    },
    {
      "date": "2025-10-05",
      "time": "08:28AM",
      "title": "FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza\n\n\n(Zacks)",
      "link": "/news/178345/fda-approves-label-extension-of-regns-cholesterol-drug-evkeeza"
    },
    {
      "date": "2025-10-05",
      "time": "06:02AM",
      "title": "Regenerons Evkeeza gains FDA approval for young HoFH patients\n\n\n(Pharmaceutical Technology)",
      "link": "https://finance.yahoo.com/m/94f0b10f-4151-3720-ae39-f2fcc9d1077d/regeneron%E2%80%99s-evkeeza-gains-fda.html"
    },
    {
      "date": "2025-10-05",
      "time": "12:36AM",
      "title": "1 Healthcare Stock with Exciting Potential and 2 We Ignore\n\n\n(StockStory)",
      "link": "/news/178081/1-healthcare-stock-with-exciting-potential-and-2-we-ignore"
    },
    {
      "date": "2025-09-26",
      "time": "07:00",
      "title": "Evkeeza (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol\n\n\n(GlobeNewswire)",
      "link": "/news/176577/evkeeza-evinacumab-dgnb-angptl3-antibody-approved-in-the-us-for-children-as-young-as-1-year-old-with-ultra-rare-form-of-high-cholesterol"
    },
    {
      "date": "2025-09-25",
      "time": "16:51",
      "title": "Why Regeneron (REGN) Shares Are Falling Today\n\n\n(StockStory)",
      "link": "/news/176235/why-regeneron-regn-shares-are-falling-today"
    },
    {
      "date": "2025-09-24",
      "time": "01:57",
      "title": "Regeneron's Phase 2 COURAGE Trial Shows Trevogrumab Combination Preserves Lean Mass in Obesity Patients on Semaglutide\n\n\n(Insider Monkey)",
      "link": "/news/174079/regenerons-phase-2-courage-trial-shows-trevogrumab-combination-preserves-lean-mass-in-obesity-patients-on-semaglutide"
    },
    {
      "date": "2025-09-23",
      "time": "15:26",
      "title": "Why Regeneron (REGN) Stock Is Down Today\n\n\n(StockStory)",
      "link": "/news/173738/why-regeneron-regn-stock-is-down-today"
    },
    {
      "date": "2025-10-05",
      "time": "09:45AM",
      "title": "Stock Market Today: Dow Up Ahead Of Powell Speech; Nvidia At Buy Point (Live Coverage)\n\n\n(Investor's Business Daily)",
      "link": "https://finance.yahoo.com/m/528531fa-7032-33b5-beb0-b49ba182d1f3/stock-market-today%3A-dow-up.html"
    },
    {
      "date": "2025-10-05",
      "time": "07:11AM",
      "title": "US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall\n\n\n(Reuters)",
      "link": "https://finance.yahoo.com/news/us-fda-declines-approve-scholar-111150021.html"
    },
    {
      "date": "2025-09-22",
      "time": "12:03",
      "title": "SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU\n\n\n(Zacks)",
      "link": "/news/172489/sny-regns-dupixent-receives-chmp-backing-for-urticaria-in-eu"
    },
    {
      "date": "2025-10-05",
      "time": "09:35AM",
      "title": "Humana initiated, Paycom upgraded: Wall Street's top analyst calls\n\n\n(The Fly)",
      "link": "https://finance.yahoo.com/news/humana-initiated-paycom-upgraded-wall-133512545.html"
    },
    {
      "date": "2025-10-05",
      "time": "12:29AM",
      "title": "Dupixent (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion\n\n\n(GlobeNewswire)",
      "link": "/news/171761/dupixent-dupilumab-to-treat-chronic-spontaneous-urticaria-csu-advances-in-eu-with-positive-chmp-opinion"
    },
    {
      "date": "2025-09-19",
      "time": "13:17",
      "title": "Can Regeneron Change The Paradigm In Multiple Myeloma - And Undercut J&J?\n\n\n(Investor's Business Daily)",
      "link": "https://www.investors.com/news/technology/regeneron-smoldering-multiple-myeloma-johnson-johnson-darzalex?mod=IBD_FV"
    },
    {
      "date": "2025-10-05",
      "time": "12:24PM",
      "title": "NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up\n\n\n(Zacks)",
      "link": "/news/171026/ntla-completes-enrollment-in-pivotal-study-on-hae-candidate-stock-up"
    },
    {
      "date": "2025-10-05",
      "time": "07:06AM",
      "title": "Arvinas reboots, cuts more staff; Porges joins Lazard\n\n\n(BioPharma Dive)",
      "link": "https://finance.yahoo.com/m/51142c0c-e295-3362-b50c-4d3781b9088d/arvinas-reboots%2C-cuts-more.html"
    },
    {
      "date": "2025-10-05",
      "time": "07:00AM",
      "title": "Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks\n\n\n(GlobeNewswire)",
      "link": "/news/170409/regeneron-donates-ebola-treatment-for-use-in-countries-most-at-risk-of-outbreaks"
    },
    {
      "date": "2025-09-18",
      "time": "00:02",
      "title": "3 Reasons to Sell REGN and 1 Stock to Buy Instead\n\n\n(StockStory)",
      "link": "/news/170529/3-reasons-to-sell-regn-and-1-stock-to-buy-instead"
    },
    {
      "date": "2025-09-17",
      "time": "14:27",
      "title": "Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies\n\n\n(Insider Monkey)",
      "link": "/news/168833/regeneron-pharmaceuticals-regn-advances-allergy-pipeline-with-two-positive-phase-3-trials-evaluating-first-in-class-antibody-blockers-of-cat-and-birch-allergies"
    },
    {
      "date": "2025-10-05",
      "time": "09:30AM",
      "title": "Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD\n\n\n(GlobeNewswire)",
      "link": "/news/168412/results-from-phase-2-courage-trial-demonstrating-potential-to-improve-quality-of-glp-1-receptor-agonist-induced-weight-loss-by-preserving-lean-mass-presented-at-easd"
    },
    {
      "date": "2025-10-05",
      "time": "07:00AM",
      "title": "Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation\n\n\n(GlobeNewswire)",
      "link": "/news/168198/regeneron-announces-positive-phase-3-trial-in-adults-with-ultra-rare-genetic-disorder-fibrodysplasia-ossificans-progressiva-fop-demonstrating-that-garetosmab-prevents-greater-than-99-of-abnormal-bone-formation"
    },
    {
      "date": "2025-09-16",
      "time": "12:30",
      "title": "Kymera initiated at Outperform on potential of lead skin drug\n\n\n(Investing.com)",
      "link": "https://finance.yahoo.com/news/kymera-initiated-outperform-potential-lead-163002861.html"
    },
    {
      "date": "2025-10-05",
      "time": "12:29PM",
      "title": "Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals\n\n\n(PR Newswire)",
      "link": "/news/167560/cancer-immunotherapy-surge-drives-258b-market-as-fda-accelerates-approvals"
    },
    {
      "date": "2025-10-05",
      "time": "11:42AM",
      "title": "Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial\n\n\n(Insider Monkey)",
      "link": "/news/167457/regeneron-pharmaceuticals-regn-releases-results-from-empower-lung-3-trial"
    },
    {
      "date": "2025-09-15",
      "time": "09:53",
      "title": "REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?\n\n\n(Zacks)",
      "link": "/news/166304/regn-loses-211-year-to-date-buy-sell-or-hold-the-sock"
    },
    {
      "date": "2025-10-05",
      "time": "08:15AM",
      "title": "BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN)\n\n\n(Insider Monkey)",
      "link": "/news/165921/bmo-capital-maintains-a-buy-on-regeneron-pharmaceuticals-regn"
    },
    {
      "date": "2025-09-14",
      "time": "01:17",
      "title": "BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT\n\n\n(Insider Monkey)",
      "link": "/news/165589/bmo-capital-maintains-a-buy-on-regeneron-pharmaceuticals-regn-sets-a-640-pt"
    },
    {
      "date": "2025-09-12",
      "time": "08:33",
      "title": "Maias NSCLC immunotherapy secures Phase II efficacy win\n\n\n(Clinical Trials Arena)",
      "link": "https://finance.yahoo.com/m/7afad917-6c5a-3e43-96b6-b7834b416270/maia%E2%80%99s-nsclc-immunotherapy.html"
    },
    {
      "date": "2025-09-11",
      "time": "12:55",
      "title": "Phase III success for Regeneron signals pozelimab and cemdisirans entry into MG market\n\n\n(Clinical Trials Arena)",
      "link": "https://finance.yahoo.com/m/44f368c5-7680-3d9b-914a-6e9191e35186/phase-iii-success-for.html"
    },
    {
      "date": "2025-10-05",
      "time": "04:57AM",
      "title": "Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?\n\n\n(Zacks)",
      "link": "/news/163411/strength-seen-in-travere-tvtx-can-its-262-jump-turn-into-more-strength"
    },
    {
      "date": "2025-09-10",
      "time": "07:33",
      "title": "Kriya, Odyssey secure megarounds; Amgen boosts R&D leadership\n\n\n(BioPharma Dive)",
      "link": "https://finance.yahoo.com/m/758c7bf5-7ace-3014-b16f-3456b9f15052/kriya%2C-odyssey-secure.html"
    },
    {
      "date": "2025-10-05",
      "time": "04:00AM",
      "title": "Pharmas new boomtown? Why drugmakers are setting up shop in a small Swiss city.\n\n\n(Pharma Voice)",
      "link": "https://finance.yahoo.com/m/f3fbe26c-ddc2-3b4c-982e-c363db95afd8/pharma%E2%80%99s-new-boomtown%3F-why.html"
    },
    {
      "date": "2025-09-09",
      "time": "15:10",
      "title": "Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy\n\n\n(Benzinga)",
      "link": "https://finance.yahoo.com/news/regenerons-libtayo-combo-achieves-nearly-191004108.html"
    },
    {
      "date": "2025-10-05",
      "time": "12:38PM",
      "title": "Regenerons cat and birch allergy mAbs score in Phase III trials\n\n\n(Clinical Trials Arena)",
      "link": "https://finance.yahoo.com/m/a3448f2c-f759-3263-a9dc-ae7589fe322f/regeneron%E2%80%99s-cat-and-birch.html"
    },
    {
      "date": "2025-10-05",
      "time": "12:28PM",
      "title": "Health Care Roundup: Market Talk\n\n\n(The Wall Street Journal)",
      "link": "https://finance.yahoo.com/m/ea88bbff-8bd9-3335-a92a-6ed9e033bacb/health-care-roundup%3A-market.html"
    },
    {
      "date": "2025-10-05",
      "time": "07:00AM",
      "title": "Libtayo (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer\n\n\n(GlobeNewswire)",
      "link": "/news/160945/libtayo-cemiplimab-plus-chemotherapy-results-at-five-years-reinforce-significant-and-durable-improvements-in-survival-outcomes-for-advanced-non-small-cell-lung-cancer"
    },
    {
      "date": "2025-09-08",
      "time": "11:27",
      "title": "NKTR Shares Surge 38.2% in a Week: Here's What You Should Know\n\n\n(Zacks)",
      "link": "/news/160184/nktr-shares-surge-382-in-a-week-heres-what-you-should-know"
    },
    {
      "date": "2025-10-05",
      "time": "06:30AM",
      "title": "Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies\n\n\n(GlobeNewswire)",
      "link": "/news/159760/regeneron-advances-allergy-pipeline-with-two-positive-phase-3-trials-evaluating-first-in-class-antibody-blockers-of-cat-and-birch-allergies"
    },
    {
      "date": "2025-09-07",
      "time": "09:15",
      "title": "2 Beaten-Down Stocks to Buy on the Dip\n\n\n(Motley Fool)",
      "link": "/news/159469/2-beaten-down-stocks-to-buy-on-the-dip"
    },
    {
      "date": "2025-09-05",
      "time": "10:11",
      "title": "RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress\n\n\n(Zacks)",
      "link": "/news/158944/rhhby-posts-positive-data-on-vabysmo-in-namd-at-euretina-congress"
    },
    {
      "date": "2025-09-04",
      "time": "16:05",
      "title": "Regeneron Announces Updated Presentation Time for Upcoming Investor Conference\n\n\n(GlobeNewswire)",
      "link": "/news/158374/regeneron-announces-updated-presentation-time-for-upcoming-investor-conference"
    },
    {
      "date": "2025-10-05",
      "time": "01:32PM",
      "title": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory\n\n\n(Insider Monkey)",
      "link": "/news/158230/regeneron-pharmaceuticals-inc-regn-a-bull-case-theory"
    },
    {
      "date": "2025-10-05",
      "time": "10:48AM",
      "title": "SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study\n\n\n(Zacks)",
      "link": "/news/157993/sny-down-despite-eczema-candidate-meeting-goal-in-phase-iii-study"
    },
    {
      "date": "2025-10-05",
      "time": "09:10AM",
      "title": "Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'\n\n\n(Investor's Business Daily)",
      "link": "https://www.investors.com/news/technology/sanofi-stock-eczema-treatment-dupixent?mod=IBD_FV"
    },
    {
      "date": "2025-09-03",
      "time": "23:32",
      "title": "Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best\n\n\n(StockStory)",
      "link": "/news/157443/immuno-oncology-q2-earnings-regeneron-nasdaq-regn-simply-the-best"
    },
    {
      "date": "2025-10-05",
      "time": "11:30AM",
      "title": "Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?\n\n\n(Zacks)",
      "link": "/news/157081/why-is-axsome-axsm-up-192-since-last-earnings-report"
    },
    {
      "date": "2025-10-05",
      "time": "10:07AM",
      "title": "MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline\n\n\n(Zacks)",
      "link": "/news/156983/mrk-posts-cholesterol-drug-data-focus-shifts-back-to-its-pipeline"
    },
    {
      "date": "2025-10-05",
      "time": "02:58AM",
      "title": "How Is Regenerons Stock Performance Compared to Other Pharma Stocks?\n\n\n(Barchart)",
      "link": "https://finance.yahoo.com/m/ebedeaaf-ffe6-3254-b912-bb54bf168299/how-is-regeneron%E2%80%99s-stock.html"
    },
    {
      "date": "2025-09-02",
      "time": "11:12",
      "title": "Evercore ISI Maintains a Buy on Regeneron Pharmaceuticals (REGN) With a $750 PT\n\n\n(Insider Monkey)",
      "link": "/news/155728/evercore-isi-maintains-a-buy-on-regeneron-pharmaceuticals-regn-with-a-750-pt"
    },
    {
      "date": "2025-08-29",
      "time": "04:51",
      "title": "Regeneron Pharmaceuticals, Inc. (REGN) Confident on Odronextamab Approval After Setbacks\n\n\n(Insider Monkey)",
      "link": "/news/153052/regeneron-pharmaceuticals-inc-regn-confident-on-odronextamab-approval-after-setbacks"
    },
    {
      "date": "2025-08-28",
      "time": "05:00",
      "title": "FDA Approves Regeneron Pharmaceuticals, Inc. (REGN)'s Linvoseltamab for Multiple Myeloma\n\n\n(Insider Monkey)",
      "link": "/news/151777/fda-approves-regeneron-pharmaceuticals-inc-regns-linvoseltamab-for-multiple-myeloma"
    },
    {
      "date": "2025-08-27",
      "time": "12:06",
      "title": "Regeneron tees up myasthenia gravis drug approval after Phase III victory\n\n\n(Clinical Trials Arena)",
      "link": "https://finance.yahoo.com/m/f5515bd2-2283-3e13-a918-0527080d7aa2/regeneron-tees-up-myasthenia.html"
    },
    {
      "date": "2025-10-05",
      "time": "09:15AM",
      "title": "What Are Wall Street Analysts Target Price for Regeneron Pharmaceuticals Stock?\n\n\n(Barchart)",
      "link": "https://finance.yahoo.com/m/82829ee9-6718-3df9-bf33-a06afdea2a39/what-are-wall-street.html"
    },
    {
      "date": "2025-08-26",
      "time": "11:17",
      "title": "Immuneering Stock Rises 21.7% on Supply Agreement With LLY\n\n\n(Zacks)",
      "link": "/news/150114/immuneering-stock-rises-217-on-supply-agreement-with-lly"
    },
    {
      "date": "2025-10-05",
      "time": "10:50AM",
      "title": "Stock Market Today: Stocks rise despite Trump threats against Fed, tech regulation\n\n\n(TheStreet)",
      "link": "https://finance.yahoo.com/m/44d579c1-bb12-3e93-82f6-200f693399c7/stock-market-today%3A-stocks.html"
    },
    {
      "date": "2025-10-05",
      "time": "08:39AM",
      "title": "The FDA Extends the Review Deadlines for Two Submissions by Regeneron Pharmaceuticals (REGN)\n\n\n(Insider Monkey)",
      "link": "/news/149759/the-fda-extends-the-review-deadlines-for-two-submissions-by-regeneron-pharmaceuticals-regn"
    },
    {
      "date": "2025-10-05",
      "time": "07:54AM",
      "title": "J&J earmarks $2B for Fujifilms North Carolina facility\n\n\n(Manufacturing Dive)",
      "link": "https://finance.yahoo.com/m/52ef3a84-901e-354c-ac1c-7e0309218b56/j%26j-earmarks-%242b-for.html"
    },
    {
      "date": "2025-10-05",
      "time": "07:00AM",
      "title": "Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis\n\n\n(GlobeNewswire)",
      "link": "/news/149502/regeneron-announces-positive-results-from-phase-3-trial-in-generalized-myasthenia-gravis"
    },
    {
      "date": "2025-08-25",
      "time": "13:59",
      "title": "FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles\n\n\n(Benzinga)",
      "link": "https://finance.yahoo.com/news/fda-flags-alarming-contamination-novo-175939597.html"
    },
    {
      "date": "2025-08-24",
      "time": "08:45",
      "title": "2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts\n\n\n(Motley Fool)",
      "link": "/news/148225/2-biotech-stocks-that-could-soar-21-and-245-according-to-wall-streets-top-analysts"
    },
    {
      "date": "2025-08-22",
      "time": "05:57",
      "title": "The Zacks Analyst Blog Highlights Health Care Select Sector SPDR, SPDR S&P 500 ETF Trust, UnitedHealth, Regeneron, CVS Health and Novo Nordisk\n\n\n(Zacks)",
      "link": "/news/147045/the-zacks-analyst-blog-highlights-health-care-select-sector-spdr-spdr-sp-500-etf-trust-unitedhealth-regeneron-cvs-health-and-novo-nordisk"
    },
    {
      "date": "2025-08-21",
      "time": "11:58",
      "title": "J&J signs $2bn incumbency deal at CDMO Fujifilms new hub\n\n\n(Pharmaceutical Technology)",
      "link": "https://finance.yahoo.com/m/7601a6f6-aa58-38ed-9501-be0ef605c955/j%26j-signs-%242bn-incumbency.html"
    },
    {
      "date": "2025-10-05",
      "time": "11:00AM",
      "title": "Is This the Right Time to Consider Healthcare ETFs?\n\n\n(Zacks)",
      "link": "/news/146554/is-this-the-right-time-to-consider-healthcare-etfs"
    },
    {
      "date": "2025-10-05",
      "time": "09:51AM",
      "title": "FDA Extends Review Period of REGN's Submission for Eylea HD\n\n\n(Zacks)",
      "link": "/news/146464/fda-extends-review-period-of-regns-submission-for-eylea-hd"
    },
    {
      "date": "2025-10-05",
      "time": "07:24AM",
      "title": "Novos facility issues delay FDA decisions on Regenerons Eylea HD\n\n\n(Pharmaceutical Technology)",
      "link": "https://finance.yahoo.com/m/685139cf-e177-3241-8faa-8a4580a355ec/novo%E2%80%99s-facility-issues-delay.html"
    },
    {
      "date": "2025-10-05",
      "time": "05:11AM",
      "title": "J&J to invest $2 billion to boost US manufacturing as drug tariffs loom\n\n\n(Reuters)",
      "link": "https://finance.yahoo.com/news/johnson-johnson-invest-2-billion-091136627.html"
    },
    {
      "date": "2025-08-20",
      "time": "17:30",
      "title": "FDA Pushes Back Eylea HD Review; Regeneron Still Gains\n\n\n(GuruFocus.com)",
      "link": "https://finance.yahoo.com/news/fda-pushes-back-eylea-hd-213057523.html"
    },
    {
      "date": "2025-10-05",
      "time": "11:19AM",
      "title": "EYLEA HD (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension\n\n\n(GlobeNewswire)",
      "link": "/news/145430/eylea-hd-aflibercept-injection-8-mg-applications-for-expanded-us-label-and-prefilled-syringe-receive-fda-review-period-extension"
    },
    {
      "date": "2025-10-05",
      "time": "10:30AM",
      "title": "Stock Market Today: Tech stocks are diving (and taking the S&P and Nasdaq with them)\n\n\n(TheStreet)",
      "link": "https://finance.yahoo.com/m/8aceed3f-9dac-307c-84c4-e61d31342459/stock-market-today%3A-tech.html"
    },
    {
      "date": "2025-08-19",
      "time": "09:33",
      "title": "Will EXEL's Share Repurchase Program Boost Value for Investors?\n\n\n(Zacks)",
      "link": "/news/144279/will-exels-share-repurchase-program-boost-value-for-investors"
    },
    {
      "date": "2025-08-15",
      "time": "10:10",
      "title": "Can Eylea HD and Dupixent Profits Revive Regeneron Stock?\n\n\n(Zacks)",
      "link": "/news/142012/can-eylea-hd-and-dupixent-profits-revive-regeneron-stock"
    },
    {
      "date": "2025-10-05",
      "time": "09:20AM",
      "title": "Veru Announces Novel Modified-Release Oral Formulation for Enobosarm\n\n\n(Zacks)",
      "link": "/news/141897/veru-announces-novel-modified-release-oral-formulation-for-enobosarm"
    },
    {
      "date": "2025-10-05",
      "time": "06:01AM",
      "title": "Financial Services Roundup: Market Talk\n\n\n(The Wall Street Journal)",
      "link": "https://finance.yahoo.com/m/6129bfa0-835e-3dcc-8d0b-63e7cfa49d82/financial-services-roundup%3A.html"
    },
    {
      "date": "2025-08-14",
      "time": "17:58",
      "title": "'Big Short' investor Burry turned more bullish on second quarter\n\n\n(Reuters)",
      "link": "https://finance.yahoo.com/news/big-short-investor-burry-turned-215841087.html"
    },
    {
      "date": "2025-10-05",
      "time": "06:05AM",
      "title": "Students Earn Top Awards at 42nd Annual Research Science Institute at MIT\n\n\n(GlobeNewswire)",
      "link": "https://finance.yahoo.com/news/students-earn-top-awards-42nd-100500443.html"
    },
    {
      "date": "2025-08-13",
      "time": "09:05",
      "title": "Here's Why You Should Consider Buying Regeneron Pharma (REGN)'s Shares\n\n\n(Insider Monkey)",
      "link": "/news/139107/heres-why-you-should-consider-buying-regeneron-pharma-regns-shares"
    },
    {
      "date": "2025-10-05",
      "time": "12:14AM",
      "title": "5 Insightful Analyst Questions From Regeneron's Q2 Earnings Call\n\n\n(StockStory)",
      "link": "/news/138023/5-insightful-analyst-questions-from-regenerons-q2-earnings-call"
    },
    {
      "date": "2025-08-12",
      "time": "23:43",
      "title": "REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges\n\n\n(StockStory)",
      "link": "/news/138398/regn-q2-deep-dive-new-indications-and-pipeline-progress-offset-eylea-challenges"
    },
    {
      "date": "2025-10-05",
      "time": "09:10AM",
      "title": "Guggenheim Lifts PT on Regeneron Pharmaceuticals (REGN) to $815 From $810\n\n\n(Insider Monkey)",
      "link": "/news/136677/guggenheim-lifts-pt-on-regeneron-pharmaceuticals-regn-to-815-from-810"
    },
    {
      "date": "2025-10-05",
      "time": "06:36AM",
      "title": "Sanofi halts Praluent supply in China due to limited availability\n\n\n(Investing.com)",
      "link": "https://finance.yahoo.com/news/sanofi-halts-praluent-supply-china-103612306.html"
    },
    {
      "date": "2025-08-11",
      "time": "20:20",
      "title": "Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners\n\n\n(Insider Monkey)",
      "link": "/news/135890/regeneron-reveals-the-regeneron-prize-for-creative-innovation-2025-winners"
    },
    {
      "date": "2025-10-05",
      "time": "07:00AM",
      "title": "Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments\n\n\n(PR Newswire)",
      "link": "https://finance.yahoo.com/news/biohaven-reports-second-quarter-2025-110000699.html"
    },
    {
      "date": "2025-08-08",
      "time": "11:19",
      "title": "Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus\n\n\n(Zacks)",
      "link": "/news/133868/intellia-q2-loss-narrower-than-expected-pipeline-progress-in-focus"
    },
    {
      "date": "2025-10-05",
      "time": "03:55AM",
      "title": "Analyst Report: Intellia Therapeutics, Inc.\n\n\n(Morningstar Research)",
      "link": "https://finance.yahoo.com/m/179ec508-0392-3c9e-8fe1-6aac989b4a2d/analyst-report%3A-intellia.html"
    },
    {
      "date": "2025-08-07",
      "time": "23:48",
      "title": "BMO Capital Lifts PT on Regeneron Pharmaceuticals (REGN) Stock, Keeps Outperform\n\n\n(Insider Monkey)",
      "link": "/news/133227/bmo-capital-lifts-pt-on-regeneron-pharmaceuticals-regn-stock-keeps-outperform"
    },
    {
      "date": "2025-10-05",
      "time": "04:05PM",
      "title": "Regeneron Announces Investor Conference Presentations\n\n\n(GlobeNewswire)",
      "link": "/news/132660/regeneron-announces-investor-conference-presentations"
    },
    {
      "date": "2025-08-06",
      "time": "11:43",
      "title": "Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y\n\n\n(Zacks)",
      "link": "/news/130288/ultragenyxs-q2-loss-narrower-than-expected-revenues-rise-yy"
    },
    {
      "date": "2025-10-05",
      "time": "10:33AM",
      "title": "Bayer Beats on Q2 Earnings and Sales, Raises '25 Adjusted Sales View\n\n\n(Zacks)",
      "link": "/news/130194/bayer-beats-on-q2-earnings-and-sales-raises-25-adjusted-sales-view"
    },
    {
      "date": "2025-08-05",
      "time": "17:45",
      "title": "Analyst Report: Sanofi\n\n\n(Morningstar Research)",
      "link": "https://finance.yahoo.com/m/e7b1d0c4-57aa-311d-ad9a-6f3a11960974/analyst-report%3A-sanofi.html"
    },
    {
      "date": "2025-10-05",
      "time": "08:00AM",
      "title": "Cisco Reinvents Digital Resilience for the Agentic Era at Splunk .conf25\n\n\n(PR Newswire)",
      "link": "https://finance.yahoo.com/news/cisco-reinvents-digital-resilience-agentic-120000737.html"
    },
    {
      "date": "2025-08-04",
      "time": "16:30",
      "title": "Onco360\u00ae Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC (linvoseltamab-gcpt)\n\n\n(GlobeNewswire)",
      "link": "https://finance.yahoo.com/news/onco360-selected-specialty-pharmacy-partner-203000940.html"
    },
    {
      "date": "2025-10-05",
      "time": "11:39AM",
      "title": "Analyst Report: Regeneron Pharmaceuticals, Inc.\n\n\n(Morningstar Research)",
      "link": "https://finance.yahoo.com/m/34f5f816-6e80-38cc-86a0-93f43daa3478/analyst-report%3A-regeneron.html"
    },
    {
      "date": "2025-10-05",
      "time": "07:36AM",
      "title": "Manufacturing issues at Novo facility disrupt Regeneron drug review\n\n\n(Pharmaceutical Technology)",
      "link": "https://finance.yahoo.com/m/12531104-70a4-35e2-b932-f65cd7a37ee9/manufacturing-issues-at-novo.html"
    }
  ]
}